1384 results about "Glucosamine" patented technology

A dietary supplement blend composition is disclosed, the basic formulation of the composition containing vitamins, minerals, and carotenoids. The composition can also contain bioflavonoids, cartilage protectors such as glucosamine or chondroitin, alpha-lipoic acid, coenzyme Q10, and a source of omega-3 fatty acids such as flax seed oil. The composition is beneficial for improving health and preventing disease, particularly for degenerative conditions. A method for supplementing the diet is also disclosed, wherein the quantity of daily rations of the dietary supplement blend composition is determined based on the person's age, body weight, and quality of diet.

The composition and method for healing tissues is a medicinal composition for facilitating the growth, protection and healing of tissues and cells in animals and humans. The composition is formulated as a either a powder, gel, paste, film, fluid injectable, rehydratable freeze-dried paste or sponge, sprayable solution, topically applied patch with adhesive and reservoir system, an intermediate for coatables such as films and bandages, a matrix for membranes, or as a matrix of flexible polymer(s), or delivered as either an orally ingestible liquid, tablet or capsule. The main ingredient of the formulated compositions is hydrolyzed collagen, which can be combined with polysulfated glycosaminoglycans, hyaluronic acid or salts thereof, or a glucosamine salt, and mixtures thereof. The composition may be formulated as an aqueous eye drop solution.

The present invention relates to a method and transdermal pharmaceutical composition for preventing or reducing the likelihood of calcium deficiency or imbalances caused by calcium deficiency. The transdermal pharmaceutical composition includes a therapeutically effective amount of a pharmaceutically acceptable salt of calcium and a pharmaceutically acceptable carrier constituting a pluronic lecithin organogel. In addition to calcium, the transdermal pharmaceutical composition may also contain a therapeutically effective amount of: (1) a pharmaceutically acceptably salt of other minerals such as magnesium, zinc, selenium, manganese, or chromium; (2) a vitamin such as vitamin A, vitamin D, vitamin C, vitamin E or B-complex vitamins, choline, lecithin, inositol, PABA, biotin, or bioflavomoids; (3) a carotenoid such as lycopene or lutein; (4) a hormone such as dehydroepiandrosterone, progesterone, pregnenolone, or melatonin; (5) an amino acid such as arginine, glutamine, lysine, phenylalanine, tyrosine, GABA, tryptophan, carnitine, or acetyl-l-carnitine; (6) a fatty acid such as a fish oil or flax seed oil; (7) a vita-nutrient such as coenzyme Q10; (8) a cartilage building nutrient such as glucosamine, chondroitin, or MSM, (9) a herb such as ginkgo biloba, echinacea, 5-HTP, St. John's wort, or saw palmetto; or (9) any combination thereof. The transdermal pharmaceutical composition may be topically administered to a human to prevent or reduce the likelihood of calcium deficiency or imbalances caused by calcium deficiency such as hypertension, high cholesterol, colon and rectal cancer, osteomalacia, rickets, osteoporosis, cardiovascular disease, preeclampsia, tooth decay, and premenstrual syndrome.

The present invention relates generally to functional sweetener compositions comprising non-caloric or low-caloric natural and / or synthetic high-potency sweeteners and methods for making and using them. In particular, the present invention relates to different functional sweetener compositions comprising at least one non-caloric or low-caloric natural and / or synthetic high potency sweetener, at least one sweet taste improving composition, and at least one functional ingredient, such as glucosamine. The present invention also relates to functional sweetener compositions and methods that can improve the tastes of non-caloric or low-caloric high-potency sweeteners by imparting a more sugar-like taste or characteristic. In particular, the functional sweetener compositions and methods provide a more sugar-like temporal profile, including sweetness onset and sweetness linger, and / or a more sugar-like flavor profile.

The invention relates to a chitosan-based transport system for overcoming the blood-brain barrier. This transport system can convey active agents or markers into the brain. The transport system contains at least one substance selected from the group consisting of chitin, chitosan, chitosan oligosaccharides, glucosamine, and derivatives thereof, and optionally one or more active agents and / or one or more markers and / or one or more ligands.

The invention relates to compositions of a deacetylated poly N-acetylated glucosamine (dPNAG) of Staphylococci. The dPNAG may be isolated from natural sources or synthesized de novo. The invention also relates to the use of dPNAG as a vaccine for inducing active immunity to infections caused by Staphylococcus aureus, S. epidermidis, other related coagulase-negative or coagulase-positive Staphylococci, and other organisms carrying the ica (intracellular adhesion) locus. The invention further provides methods of use for antibodies directed to dPNAG, particularly for inducing passive immunity to the same class of infections.

The present invention relates to the enzymatic synthesis of oligosaccharides, including sialylated product saccharides. In particular, it relates to the use of recombinant cells to take up low cost precursors such as glucose, pyruvate and N-actyl-glucosamine, and to synthesize activated sugar moieties that are used in oligosaccharide synthesis. The methods make possible the synthesis of many oligosaccharides using microorganisms and readily available, relatively inexpensive starting materials.

Compositions and methods for dual imaging and for dual chemotherapy and radiotherapy are disclosed. More particularly, the invention concerns compounds comprising the structure X1-Y-X2, wherein Y comprises two or more carbohydrate residues covalently attached to one another, X1 and X2 are diagnostic or therapeutic moieties covalently attached to Y, provided that when Y does not comprise a glucosamine residue, X1 and X2 are diagnostic moieties. The present invention also concerns methods of synthesis of these compounds, application of such compounds for dual imaging and treatment of hyperproliferative disease, and kits for preparing a radiolabeled therapeutic or diagnostic compound.

The invention relates generally to a formulation which may comprise additional vitamins, minerals, herbs and supplements and methods for using the same for joint pain relief. The formulation may comprise supplements such as glucosamine, hyaluronic acid and methylsulfonylmethane (MSM) and acetaminophen for acute joint pain. The invention also encompasses methods for joint pain relief with the formulation described herein.

The present invention provides covalent conjugates between a polypeptide and a modifying group, such as a water-soluble polymer (e.g., PEG). The amino acid sequence of the polypeptide includes one or more O-linked glycosylation sequence, each being a substrate for a GIcNAc transferase. The modifying group is covalently linked to the polypeptide via a glycosyl-linking group interposed between and covalently linked to both the polypeptide and the modifying group. In one embodiment, a glucosamine linking group is directly attached to an amino acid residue of the O-linked glycosylation sequence. The invention further provides methods of making polypeptide conjugates. The present invention also provides non-naturally occurring polypeptides that include at least one O-linked linked glycosylation sequence of the invention, wherein each glycosylation sequence is a substrate for a GIcNAc transferase. The invention further provides pharmaceutical compositions that include a polypeptide conjugate of the invention.

The invention provides an anti-stress fermentation protein feed which is produced by composite bacterium inoculation and high-temperature and moderate-temperature fermentation of a plant derived protein raw material, a terrestrial animal derived protein raw material and a marine animal derived protein raw material. Macromolecular substances in the protein feed are digested and decomposed into micromolecular substances, stressors in nutritional ingredients are decreased, anti-stress active factors such as genistein, glutathione and glucosamine are increased, the immunity of fed animals is improved, and the protein feed shows a good anti-stress capability. The invention further provides a producing method of the anti-stress fermentation protein feed. The feed product with high functionality, good anti-stress effect and high economical efficiency is obtained with the adoption of the multiple derived protein raw materials, a specific formula and an appropriate matching ratio and by mixed fermentation through a special secondary fermentation process.

The invention discloses a microwave-assisted method for preparing carbon quantum dots rich in amino groups on the surfaces thereof and application of the amino carbon quantum dots. The method comprises the following steps: using aqueous solution of glucosamine phosphate as a raw material, heating the raw material with a microwave oven as a reaction platform to obtain carbon quantum dots with fluorescent properties, and removing residues and moisture by dialysis and rotary evaporation to obtain carbon quantum dot powder. The method provided by the invention for preparing amino carbon quantum dots is simple in operation and easy in generalization, has low cost, high yield, simple preparation process and equipment, and can complete the operation in a very short time. The obtained carbon quantum dots are rich in amino groups on the surfaces thereof and soluble in water, the fluorescence quantum yield is greatly increased, and the carbon quantum dots are successfully used for labeling living cells, therefore the method has broad application prospects.

The present invention relates to methods and compositions for the treatment of skin-related conditions and disorders. In one aspect, the invention features methods and compositions for the transdermal delivery of compounds for the treatment of skin-related conditions and disorders, wherein the compositions include meglumine and a liposome component.

This invention provides methods and formulations for treating an inflammatory disease or reducing an inflammatory reaction comprising administering a fortified formulation comprising stabilized rice bran derivative and a fortification agent. Preferred rice bran derivatives are rice bran oil and the solubilized fraction of rice bran. Preferred fortification agents are glucosamine derivative, methylsulfonylmethane, yucca concentrate, and grape seed extract.

The invention discloses a wide-spectrum plant cold-resisting agent for plants such as food crops, economic crops, vegetables, fruit trees, economic trees, flowers, and lawns. The active component of the agent is chitosanoligosaccharide or a derivative thereof. The chitosanoligosaccharide is oligosaccharide of glucosamine linked through beta-1,4-glucosidic bond, and has a molecular weight of 300-10000Da, and a deacetylation degree of 50-100%. The chitosanoligosaccharide derivatives are chitosanoligosaccharide sulfuric acid derivative, chitosanoligosaccharide hydrochloric acid derivative, chitosanoligosaccharide phosphoric acid derivative, chitosanoligosaccharide sulfonamide derivative, chitosanoligosaccharide acyl isothiocyanate derivative, chitosanoligosaccharide phosphoric derivative, chitosanoligosaccharide guanidine derivative, chitosanoligosaccharide nicotinicacyl isothiocyanate derivative, chitosanoligosaccharide-cerium (IV) complex, and the like.

Compositions useful for treating inflammatory diseases including arthritis are disclosed which comprise cetyl myristoleate compounds or related compounds and at least one compound useful for treatment of inflammatory disease, such as tetracycline compounds, Cox-2 inhibitors, non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, local anaesthetics, chelating agents, matrix metalloprotease inhibitors, inhibitors of inflammatory cytokines, glucosamine, chondroitin sulfate and collagen hydrolysate. Also disclosed are pharmaceutical compositions and methods of treatment for inflammatory disease and local inflammation and dermal irritation. Also disclosed are compositions including tetracycline and at least one compound useful for treatment of inflammatory disease.

The objetive of the present invention was to enhance the skin whitening effects and blackening prevention effects and supply safe and stable topical agents for dermatological use. For that purpose 4-Hydroxyphenyl-alpha-D-glucopyranoside was combined with auxiliary agents such as ascorbic acid and its derivatives, crude drugs and its extracts, hydroxycarboxylic acid and its salts, oil soluble glycyrrhiza extract, gentian extract, phenol derivatives and their salts, placenta extract, kojic acid and its derivative, glucosamine and its derivatives, azelaic acid and its derivatives, retinol and its derivatives, pyridoxin and its derivatives, tocopherol and its derivatives, chitosan and its decomposition products, caffeic acid derivatives, hydroxycinnamate and its derivatives, Umbelliferae plant extracts, mycelial cultures and their extracts, plant leaves and their extracts.

Improved treatments of joint diseases, such as, e.g. osteoarthritis and rheumatoid arthritis, and pain, wherein a strontium-containing compound is administered alone or in combination with one or more second therapeutically and / or prophylactically active substances, selected from the group consisting of bisphosphonates, glucosamine, pallitative agents, analgesic agents, disease modifying anti-rheumatic compounds (DMARDs), selective estrogen receptor modulators (SERMs), aromatase inhibitors, non-steroidal anti-inflammatory agents (NSAIDs), COX-2 inhibitors, COX-3 inhibitors, opioids, inhibitors / antagonists of IL-1, inhibitors / antagonists of TNF-alpha, inhibitors of matrix metallo-proteinases (MMPs), cathepsin K inhibitors, inhibitors / antagonists of RANK-ligand, statins, glucocorticoids, chondroitin sulphate, NMDA receptor antagonists, inhibitors of interleukin-I converting enzyme, Calcitonin gene related peptide antagonists, glycine antagonists, vanilloid receptor antagonists, inhibitors of inducible nitric oxide synthetase (iNOS), N-acetylcholine receptor agonists, neurokinin antagonists, neuroleptic agents, PAR2 receptor antagonists and anabolic growth factors acting on joint tissue components. Pharmaceutical compositions comprising a strontium-containing compound and a second therapeutically and / or prophylactically active substance as defined above.

The composition and method for healing tissues is a medicinal composition for facilitating the growth, protection and healing of tissues and cells in animals and humans. The composition is formulated as a either a powder, gel, paste, film, fluid injectable, rehydratable freeze-dried paste or sponge, sprayable solution, topically applied patch with adhesive and reservoir system, an intermediate for coatables such as films and bandages, a matrix for membranes, or as a matrix of flexible polymer(s), or delivered as either an orally ingestible liquid, tablet or capsule. The main ingredient of the formulated compositions is hydrolyzed collagen, which can be combined with polysulfated glycosaminoglycans, hyaluronic acid or salts thereof, or a glucosamine salt, and mixtures thereof. The composition may be formulated with differing concentrations of PSGAG.

A method of preventing or treating pain or inflammation in a subject is provided by administering to the subject a Cox-2 inhibitor and a polyunsaturated fatty acid, or a prodrug thereof, wherein the amount of a Cox-2 inhibitor and polyunsaturated fatty acid or a pharmaceutically acceptable salt or prodrug thereof together constitute a pain or inflammation suppressing treatment or prevention effective amount. Glucosamine and / or chondroitin can optionally be present. Therapeutic compositions that contain the combination of Cox-2 inhibitor and polyunsaturated fatty acid and, optionally, the glucosamine and / or chondroitin, are disclosed, as are pharmaceutical compositions.

The invention relates to health food for enhancing human immunity and increasing bone mineral density and a preparation method thereof; the health food of the invention comprises the following components: hyaluronic acid, glucosamine, collagen, kudzu root extracts, chondroitin sulfate, vitamins, calcium, etc; because of the embedding processing of hyaluronic acid, the defect of property change of hyaluronic acid due to moisture absorption and influence of environmental factors is overcome; the health food prepared by the organic combination of the embedded hyaluronic acid with glucosamine, collagen, plant extracts, vitamins, mineral matter and the like has functions and effects which can supplement each other, has the effects of lubricating joints, increasing bone mineral density, and enhancing bone strength during long-term administration, and also has the functions of delaying aging, removing freckles and beautifying faces, and the like; the health food of the invention can be prepared into powder, granules, tablets, capsules, is convenient for carrying and taking, has stable and lasting efficacy, has no side effects, and is an ideal health food of patients with hypoimmunity and osteoporosis.

The present invention herein provides a chitosan-containing polysaccharide and a method for the preparation thereof as well as a medicine and a food containing the polysaccharide.The chitosan-containing polysaccharide is prepared by a method comprising the steps of heat-treating a fungus in a concentrated aqueous caustic alkali solution; subjecting the resulting solution to a solid-liquid separation treatment; dissolving the resulting solid contents in an aqueous organic acid solution; adding, to the resulting solution, an alcohol or a caustic alkali to thus form precipitates; washing the resulting precipitates; and then drying them. This chitosan-containing polysaccharide is a compound in which homopolymers of glucosamine are linked with glucan through covalent bonds; it has a molar ratio of glucosamine and glucose constituting the polysaccharide ranging from 1:5 to 5:1; it has a molecular weight of about 150,000; and it does not contain any β(1→3) bonds, but comprises β(1→4) bonds and β(1→6) bonds. The polysaccharide is free of any protein and reducing polysaccharide. The chitosan-containing polysaccharide is effective for the treatment or prevention of any diseases originated from living habits or customs such as hypertension and diabetes.

A pet treat comprises a frozen mixture, the frozen mixture including protein, water, and a therapeutic substance such as glucosamine and / or chondroitin. The frozen mixture can be homogenized and further include entrained air bubbles, and optionally may have a meat flavor such as beef, chicken, lamb, or pork. A support structure, such as a stick, cone, push-up tube, or cup, can be provided to facilitate provision of the pet treat to the pet.

A therapeutic composition and methods for the treatment and prevention of a degenerative joint disorder and / or a cardiovascular disease comprising polycosanols, glucosamine and chondroitin are disclosed.

The invention discloses a high-yield N-acetylglucosamine metabolic engineering bacterium, as well a construction method and applications thereof. The engineering bacterium is a recombinant Escherichia coli by leading a coded UDP-N-acetylglucosamine epimerase gene and a coded 6-glucosamine phosphate synthetase gene into Escherichia coli for expression, and knocking out the gene N-acetylglucosamine in the Escherichia coli to decompose and utilize metabolic pathway enzyme; and the constructed engineering bacterium strain utilizes glucose as a substrate for fermenting and culturing and synthesizing the N-acetylglucosamine. The engineering bacterium is high in the fermenting level of synthesizing the N-acetylglucosamine by utilizing glucose, the accumulation of side products is less, and industrial production potential capability can be achieved.

The invention provides pharmaceutical compositions, particularly vaccine compositions, employing an adjuvant system comprising RC-529 (an aminoalkyl glucosaminide phosphate compound) and QS-21 (a saponin). Such compositions synergistically enhance the immune response in a mammal to a co-administered antigen. Also provided are methods of using the compositions in the treatment of various human diseases, including cancer, microbial infections and autoimmune disorders.